Patient characteristics and follow-up of patients with HCL retreated after vemurafenib
| Patient . | Retreatment . | Vemurafenib dose . | Response . | Time to retreatment (mo) . |
|---|---|---|---|---|
| Heidelberg 01 | Vemurafenib | 2 × 240 | Blood count recovery | 14 |
| Heidelberg 03 | Vemurafenib | 2 × 240 continues retreatment | PR | 9 |
| Heidelberg 05 | R-Vemurafenib | 2 × 240 | Blood count recovery | 6 |
| Cambridge | Vemurafenib | 2 × 240 continues retreatment | PR | 25 |
| Innsbruck 02 | Vemurafenib | 1 × 240 | Blood count recovery | 11 |
| Nice 01 | Vemurafenib | 2 × 240 (5 mo) and 1 × 240 continuously | Blood count recovery | 14 |
| Heidelberg 02 | R-Pentostatin | CR | 12 | |
| Nice 02 | Cladribine | Blood count recovery | 4 | |
| Innsbruck 04 | Obinutuzumab | Ongoing treatment | 3 |
| Patient . | Retreatment . | Vemurafenib dose . | Response . | Time to retreatment (mo) . |
|---|---|---|---|---|
| Heidelberg 01 | Vemurafenib | 2 × 240 | Blood count recovery | 14 |
| Heidelberg 03 | Vemurafenib | 2 × 240 continues retreatment | PR | 9 |
| Heidelberg 05 | R-Vemurafenib | 2 × 240 | Blood count recovery | 6 |
| Cambridge | Vemurafenib | 2 × 240 continues retreatment | PR | 25 |
| Innsbruck 02 | Vemurafenib | 1 × 240 | Blood count recovery | 11 |
| Nice 01 | Vemurafenib | 2 × 240 (5 mo) and 1 × 240 continuously | Blood count recovery | 14 |
| Heidelberg 02 | R-Pentostatin | CR | 12 | |
| Nice 02 | Cladribine | Blood count recovery | 4 | |
| Innsbruck 04 | Obinutuzumab | Ongoing treatment | 3 |
R, rituximab.